Relay Medical (RELA) subsidiary Glow LifeTech has secured exclusive North American rights to ArtemiC following a successful COVID-19 phase II clinical trial.
Glow executed an agreement with Swiss Pharmacan AG on February 16, 2021, which states that Glow has exclusive rights to market, sell and distribute ArtemiC as a food supplement in Canada, U.S., Mexico and all Carribean countries.
ArtemiC is a clinically tested natural health product that contains four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C.
It is based on Glow's MyCell Technology, a delivery system that increases bioavailability and effectiveness of natural active ingredients.
The supplement was a collaborative development effort with Glow's strategic partners, Swiss PharmaCan AG and MGC Pharma. MGC Pharma will manufacture it under EU-GMP.
According to Rob Carducci, Chief Commercial Officer of Glow LifeTech,
“This is a significant new product opportunity for Glow and our shareholders, as ArtemiC shows promising results that it may improve the clinical recovery of COVID-19 patients.”
Recently, MGC announced the results of a phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the placebo group.
All of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group.
“We continue to be encouraged with the broad applications of MyCell delivery technology and Glow's commitment to bring scientifically-validated products to market,” said Yoav Raiter, CEO of Relay Medical.
Relay Medical is a technology developer and innovator focused on the development of novel technologies in the diagnostics and AI data science sectors.
Glow LifeTech is a biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness.
Relay Medical (RELA) is up 19.3 per cent and is currently trading at $0.68 per share as of 1:59 pm EST.